Long-term follow-up of HLA-A2+ patients with high-risk, hormone-sensitive prostate cancer vaccinated with the prostate specific antigen peptide homologue (PSA146-154).
Twenty-eight HLA-A2+ patients with high-risk, locally advanced or metastatic, hormone-sensitive prostate cancer were immunized with a peptide homologue of prostate-specific antigen, PSA146-154, between July 2002 and September 2004 and monitored for clinical and immune responses. Fifty percent of the patients developed strong PSA146-154-peptide-specific delayed-type hypersensitivity skin responses, tetramer and/or IFN-γ responses within one year. Thirteen patients had stable or declining serum levels of PSA one year post-vaccination. A decreased risk of biochemical progression was observed in patients who developed augmented tetramer responses at six months compared to pre-vaccination levels (P = .02). Thirteen patients have died while 15 patients remain alive with a mean overall survival of 60 months (95% CI, 51 to 68 months) per Kaplan-Meier analysis. A trend towards greater overall survival was detected in men with high-risk, hormone-sensitive CaP who developed specific T-cell immunity following vaccination with PSA146-154 peptide.
Section of Hematology and Oncology, Department of Medicine, College of Medicine Research Building, University of Illinois at Chicago, 909 South Wolcott Avenue, Chicago, IL 60612, USA.
Supriya
S
Perambakam
Hui
H
Xie
Seby
S
Edassery
David J
DJ
Peace
D000368:Aged; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D015789:HLA-A2 Antigen / Q000378:metabolism; D006728:Hormones / Q000276:immunology; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007371:Interferon-gamma / Q000096:biosynthesis; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000276:immunology*; D010455:Peptides / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000276:immunology*; D017430:Prostate-Specific Antigen / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000276:immunology*; D011471:Prostatic Neoplasms / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D012307:Risk Factors; D014611:Vaccination
D019496:Cancer Vaccines; D015789:HLA-A2 Antigen; D006728:Hormones; D010446:Peptide Fragments; D010455:Peptides; C512543:prostate-specific antigen (146-154); D007371:Interferon-gamma; D017430:Prostate-Specific Antigen
Int J Cancer. 2006 Nov 15;119(10):2428-34
16977630
Cancer. 2009 Aug 15;115(16):3670-9
19536890
Prostate. 1997 Feb 1;30(2):73-8
9051144
Cancer Immunol Immunother. 2002 Jul;51(5):263-70
12070713
Ann Oncol. 2005 May;16 Suppl 4:iv80-84
15923436
J Clin Oncol. 2010 Mar 1;28(7):1099-105
20100959
Cancer Immunol Immunother. 2010 May;59(5):663-74
19890632
Hum Immunol. 2010 Apr;71(4):383-91
20079393
Prostate. 2000 May 1;43(2):88-100
10754524
J Exp Med. 1999 Dec 6;190(11):1669-78
10587357
J Clin Oncol. 2005 Oct 20;23(30):7536-45
16157940
Cancer Immunol Immunother. 2006 Sep;55(9):1033-42
16283303
J Immunother. 2001 Jan-Feb;24(1):66-78
11211150
J Clin Oncol. 2002 Jun 1;20(11):2624-32
12039923
Nat Med. 1998 Mar;4(3):328-32
9500607
Blood. 2002 Mar 1;99(5):1517-26
11861263
Cancer Res. 2007 Apr 15;67(8):3845-52
17440099
Blood. 1996 Jul 1;88(1):202-10
8704175
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
19474385
Immunol Rev. 2007 Dec;220:129-50
17979844
Nucleic Acids Res. 2003 Feb 15;31(4):e15
12582260
Cancer Res. 2001 Sep 1;61(17):6451-8
11522640
Mol Cell Biochem. 2008 Jul;314(1-2):113-21
18421422